J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Therapeutic Options and Cost Considerations in the Treatment of Ischemic Heart Disease
John G.F. Cleland,Andrew Walker +1 more
TL;DR: In patients with well-controlled symptoms on medical therapy, the benefits of surgery are small and uncertain, and therefore medical therapy is the most cost-effective treatment, and the preferred cost- effective option favored medical treatment.
Journal ArticleDOI
Anemia and chronic heart failure: are we asking the right questions?
TL;DR: The study by van der Meer et al in this issue offers insight into the mechanism of anemia in heart failure in patients without obvious hematinic deficiency, and it is somewhat surprising to find that treatments that improve heart failure can exacerbate anemia.
Journal ArticleDOI
Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial
Licette C. Y. Liu,Mattia A.E. Valente,Douwe Postmus,Christopher M. O'Connor,Marco Metra,Howard C. Dittrich,Piotr Ponikowski,John R. Teerlink,Gad Cotter,Beth A. Davison,John G.F. Cleland,Michael M. Givertz,Daniel M. Bloomfield,Dirk J. van Veldhuisen,Hans L. Hillege,Peter van der Meer,Adriaan A. Voors +16 more
TL;DR: Biomarkers are superior to clinical characteristics to study treatment heterogeneity in acute heart failure and interactions between several biomarkers and rolofylline are found.
Journal ArticleDOI
Future research prioritization in cardiac resynchronization therapy
Marat Fudim,Frederik Dalgaard,Sana M. Al-Khatib,Daniel J. Friedman,Kathryn R Lallinger,William T. Abraham,John G.F. Cleland,Anne B. Curtis,Michael R. Gold,Valentina Kutyifa,Cecilia Linde,Daniel E. Schaber,Anthony Tang,Fatima Ali-Ahmed,Sarah A. Goldstein,Brystana G. Kaufman,Robyn Fortman,J. Kelly Davis,Lurdes Y. T. Inoue,Gillian D Sanders +19 more
TL;DR: Evidence gaps presented in this article highlight numerous, important clinical and policy questions for which there is inconclusive evidence on the role of CRT and provide a framework for future collaborative research.
Journal ArticleDOI
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
G. Michael Felker,John J.V. McMurray,John G.F. Cleland,Christopher M. O'Connor,John R. Teerlink,Adriaan A. Voors,Jan Belohlavek,Michael Böhm,Maria Borentain,Héctor Bueno,Robert T. Cole,Mary M. DeSouza,Justin A. Ezekowitz,Gerasimos Filippatos,Ninian N. Lang,Paul D. Kessler,Felipe Martinez,Alex Mebazaa,Marco Metra,Arend Mosterd,Peter S. Pang,Piotr Ponikowski,Naoki Sato,Dietmar A. Seiffert,June Ye +24 more
TL;DR: Cimlanod at a dose of 6 μg/kg/min was reasonably well-tolerated compared with placebo, and n-terminal pro-B-type natriuretic peptide and bilirubin decreased during infusion of cIMlanod treatment compared with Placebo, but these differences did not persist after treatment discontinuation.